These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36726477)

  • 61. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Profile of suvorexant in the management of insomnia.
    Sutton EL
    Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Suvorexant: a promising, novel treatment for insomnia.
    Lee-Iannotti JK; Parish JM
    Neuropsychiatr Dis Treat; 2016; 12():491-5. PubMed ID: 26955275
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Suvorexant for insomnia in older adults: a perspective review.
    Tampi RR; Manikkara G; Balachandran S; Taparia P; Hrisko S; Srinivasan S; Tampi DJ
    Drugs Context; 2018; 7():212517. PubMed ID: 29445409
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
    Nishimura S; Nakao M
    J Med Econ; 2018 Jul; 21(7):698-703. PubMed ID: 29667471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prescription Drugs Used in Insomnia.
    Dujardin S; Pijpers A; Pevernagie D
    Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
    Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suvorexant: a novel therapy for the treatment of insomnia.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia.
    Nakamura M; Nagamine T
    Innov Clin Neurosci; 2017; 14(3-4):30-37. PubMed ID: 28584695
    [No Abstract]   [Full Text] [Related]  

  • 71. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
    Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
    Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia.
    Onge ES; Phillips B; Rowe C
    J Pharm Technol; 2022 Oct; 38(5):297-303. PubMed ID: 36046352
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Iwata N
    PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant.
    Okino K; Suzuki H; Tomioka H; Sanada K; Kawai K; Iwanami A; Inamoto A
    Hum Psychopharmacol; 2023 May; 38(3):e2868. PubMed ID: 36960814
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is suvorexant a better choice than alternative hypnotics?
    Kripke DF
    F1000Res; 2015; 4():456. PubMed ID: 26594338
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Daridorexant for the Treatment of Insomnia.
    Robinson CL; Supra R; Downs E; Kataria S; Parker K; Kaye AD; Viswanath O; Urits I
    Health Psychol Res; 2022; 10(3):37400. PubMed ID: 36045942
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.